NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

"Does it not concern you that KCH, in 2015, after years of recruiting trial patients with ‘GBM4’, should make such a prognosticative error, because, if they were putting patients forward that had, in reality, a more than a fair chance of long term survival without the vaccine, do you not see how that patient selection could bias the results ? "

Yes, if this were true, it would artificially increase the number of the 5 year
treatment survivors but it would not explain the unusually long mOS of the
survivors who died before 5 years nor does it explain the unusually long
survival of the group of 64 crossovers whose progression documents
that they were genuine rGBM patients.

Furthermore, if there were a substantial number of misdiagnosed non GBM
patients in the trial, how does one explain the fact that the mOS of the
unmethylated GBM treatment patients in the trial was not statistically
different than the mOS of the unmethylated ECAs?

Finally, it is not possible to dismiss the enormous efficacy of the DCVax-L-poly ICLC
combo treatment that would never have been expressed by employing the
DCVax-L maturation agent (adjuvant) alone.

My guess is that perhaps Nemesis was one of the few or the only misdiagnosed
patient who luckily for the trial, never became a part of its statistics.